Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonsense Mutation Aniridia: An Ataluren (PTC124) Phase 2 Extension Study

NCT04117880 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT04117880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04117880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonsense Mutation Aniridia: An Ataluren (PTC124) Phase 2 Extension Study
Lead sponsor
PTC Therapeutics
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2018
Completion date
January 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aniridia